Asia Pacific Viscosupplementation Market Report by Product, Application, End User, Countries and Companies Analysis 2026-2034

Asia Pacific Viscosupplementation Market Size and Forecast 2026-2034

Asia Pacific Viscosupplementation Market is expected to reach US$ 4.18 Billion by 2034 from US$ 1.76 Billion in 2025, with a CAGR of 10.1% from 2026 to 2034. The Asia Pacific viscosupplementation market is driven by rising osteoarthritis prevalence, rapidly aging populations, increasing preference for minimally invasive treatments, expanding healthcare infrastructure, and growing awareness of non-surgical pain management options that help delay or reduce the need for joint replacement procedures.

Asia Pacific Viscosupplementation Industry Overview

Viscosupplementation is a medical procedure used primarily to manage knee osteoarthritis by injecting hyaluronic acid-based solutions directly into the affected joint. Hyaluronic acid is a naturally occurring substance found in synovial fluid that lubricates and cushions joints. In patients with osteoarthritis, the concentration and quality of this fluid decline, leading to pain, stiffness, and reduced mobility. Viscosupplementation aims to restore joint lubrication, improve shock absorption, reduce discomfort, and enhance movement. The procedure is typically recommended for patients who have not achieved adequate relief from physical therapy, lifestyle modifications, or conventional pain medications and wish to postpone surgery.

The Asia Pacific viscosupplementation market is witnessing steady growth due to increasing incidences of osteoarthritis, expanding elderly populations, and growing demand for non-surgical treatment options. Rising healthcare expenditures and improved access to orthopedic care are enabling wider adoption of viscosupplementation therapies across emerging and developed economies. Patients are increasingly seeking treatments that provide pain relief while delaying joint replacement surgeries. Additionally, advancements in hyaluronic acid formulations, increasing physician awareness, and favorable healthcare infrastructure development are supporting market expansion. Countries such as China, Japan, India, and Australia are experiencing heightened demand due to demographic changes and growing focus on musculoskeletal health management.

Recent Developments in Asia Pacific Viscosupplementation Market

• In August 2025, Ono Pharmaceutical and Seikagaku Corporation signed a definitive agreement for the co-development and commercialization of Gel-One in Japan. Gel-One is a single-injection cross-linked hyaluronic acid viscosupplement developed for osteoarthritis treatment. The product is undergoing Phase III clinical studies for both knee and hip osteoarthritis, highlighting growing investment in next-generation viscosupplementation therapies within the Japanese market.
• In July 2024, LG Chem announced the commercialization of its single-injection hyaluronic acid therapy, Synovian (Hyruan ONE), in China through a partnership with Yifan Pharmaceutical. The product is designed for knee osteoarthritis treatment and enables pain management through a single administration, improving patient convenience compared with multi-injection regimens. The launch strengthened LG Chem's presence in one of the largest osteoarthritis treatment markets in Asia-Pacific.

Growth Drivers for the Asia Pacific Viscosupplementation Market

Strategic Consolidation and Platform Expansion Strengthening Telemedicine Ecosystems

The growing prevalence of osteoarthritis is a primary factor driving demand for viscosupplementation treatments across Asia Pacific. Population aging is accelerating throughout the region, particularly in Japan, China, South Korea, and Australia, resulting in a larger patient pool requiring long-term management of degenerative joint disorders. Osteoarthritis remains one of the leading causes of disability among older adults and significantly impacts mobility and quality of life. Consequently, healthcare providers are increasingly adopting viscosupplementation as a minimally invasive option to alleviate symptoms and delay surgical intervention.

Recent innovation is further strengthening the treatment landscape. In January 2026, Biosplice Therapeutics announced the submission of its New Drug Application for Lorecivivint, a novel injectable therapy for knee osteoarthritis designed to improve pain, function, and joint health. The company highlighted the therapy's potential disease-modifying benefits in osteoarthritis management. Such advancements underscore the industry's focus on expanding treatment alternatives beyond conventional pain management approaches and are expected to support sustained growth in viscosupplementation and related joint preservation therapies.

Technological Advancements in Injectable Joint Therapies

Continuous innovation in hyaluronic acid formulations and injectable orthopedic therapies is enhancing the effectiveness of viscosupplementation procedures. Manufacturers are investing in cross-linked hyaluronic acid technologies, extended-duration formulations, and biologically enhanced products that improve lubrication and provide longer-lasting symptom relief. These developments are increasing physician confidence and encouraging wider adoption among osteoarthritis patients seeking alternatives to surgery.

A significant industry development occurred in February 2026 when Galderma announced the launch of new hyaluronic acid-based injectable products in Japan, expanding its portfolio of advanced hyaluronic acid technologies in the Asia-Pacific region. Although targeted toward medical aesthetics, the launch highlights continued investment in next-generation hyaluronic acid platforms and manufacturing capabilities that contribute to broader innovation across injectable hyaluronic acid applications. The advancement of sophisticated hyaluronic acid technologies is expected to positively influence future viscosupplementation product development and adoption.

Increasing Preference for Minimally Invasive Orthopedic Treatments

Patients and healthcare providers are increasingly favoring minimally invasive interventions that reduce hospitalization, recovery time, and procedural risks. Viscosupplementation offers an attractive option for patients experiencing moderate osteoarthritis symptoms who are not yet candidates for joint replacement surgery. The procedure can be performed in outpatient settings, making it convenient and cost-effective for both patients and healthcare systems.

Product innovation continues to support this trend. In April 2025, Evolus commercially launched Evolysse Form and Evolysse Smooth, advanced injectable hyaluronic acid gels developed using innovative formulation technologies. While designed for aesthetic applications, the launch demonstrates ongoing advancements in hyaluronic acid science and injectable product development. Increasing investments in hyaluronic acid-based therapeutics, coupled with growing patient preference for non-surgical treatment options, are expected to accelerate research and commercialization activities within the viscosupplementation market over the coming years.

Challenges in the Asia Pacific Viscosupplementation Market

Variability in Clinical Outcomes and Treatment Effectiveness

One of the major challenges facing the viscosupplementation market is the variability in treatment outcomes among patients. While many individuals experience meaningful pain relief and improved mobility, others report limited or short-term benefits. Factors such as disease severity, age, body weight, joint condition, and injection technique can influence treatment effectiveness. This inconsistency has led to differing clinical recommendations across healthcare systems and professional organizations. Furthermore, some physicians continue to favor corticosteroid injections or surgical interventions for advanced osteoarthritis cases. Variability in product formulations and treatment protocols also complicates standardization efforts. These factors may limit physician confidence and influence reimbursement decisions, creating barriers to broader adoption of viscosupplementation therapies across Asia Pacific healthcare markets.

Cost Constraints and Limited Reimbursement Coverage

The relatively high cost of viscosupplementation therapy remains a significant obstacle in several Asia Pacific countries. Multiple injection regimens and repeat treatment cycles can create financial burdens for patients, particularly in markets where reimbursement support is limited. Public healthcare systems often prioritize essential treatments, leaving patients responsible for a substantial portion of viscosupplementation expenses. In developing economies, affordability concerns may encourage patients to choose lower-cost pain management options despite potentially lower long-term benefits. Additionally, disparities in insurance coverage and reimbursement policies across countries create unequal access to treatment. Expanding reimbursement frameworks and generating stronger real-world evidence demonstrating cost-effectiveness will be essential for improving patient access and supporting sustained market growth throughout the region.

China Viscosupplementation Market

China represents one of the fastest-growing viscosupplementation markets in Asia Pacific due to its large aging population and increasing prevalence of osteoarthritis. Rising healthcare expenditures, expanding orthopedic care facilities, and growing awareness of non-surgical joint treatments are supporting market growth. The government's healthcare modernization initiatives are improving access to musculoskeletal care across urban and rural regions. According to China's National Bureau of Statistics, approximately 310 million people were aged 60 years and above in 2024, accounting for more than 22% of the country's population. This demographic shift is significantly increasing demand for osteoarthritis management solutions, including viscosupplementation therapies. Growing adoption of minimally invasive procedures and improved healthcare accessibility are expected to sustain strong market expansion in China over the coming years.

Japan Viscosupplementation Market

Japan remains a mature and highly attractive market for viscosupplementation due to its rapidly aging population and well-established healthcare infrastructure. The country has one of the highest proportions of elderly individuals globally, making osteoarthritis a significant public health concern. Japanese physicians have extensive experience utilizing hyaluronic acid-based therapies for joint disorders, contributing to strong market penetration. According to Japan's Ministry of Internal Affairs and Communications, people aged 65 years and older accounted for approximately 29.3% of the national population in 2024. This demographic profile continues to create substantial demand for osteoarthritis treatment solutions. Increasing focus on maintaining mobility and quality of life among older adults is expected to support continued utilization of viscosupplementation therapies throughout Japan.

India Viscosupplementation Market

India's viscosupplementation market is expanding steadily due to increasing awareness of osteoarthritis management, rising healthcare expenditure, and improving access to orthopedic services. Growing urbanization, sedentary lifestyles, obesity prevalence, and an expanding elderly population are contributing to a higher burden of knee osteoarthritis. Healthcare providers are increasingly recommending minimally invasive therapies that can delay knee replacement procedures and improve patient quality of life. By 2036, there will be over 230 million elderly citizens in India, accounting for 15% of the country's total population. This demographic trend is expected to significantly increase demand for osteoarthritis treatments. Improving healthcare infrastructure and growing patient awareness are likely to support long-term market growth across India.

Australia Viscosupplementation Market

Australia is a well-established market for viscosupplementation, supported by a sophisticated healthcare system, strong orthopedic care infrastructure, and increasing awareness of joint health management. The growing incidence of osteoarthritis, coupled with an aging population, is encouraging demand for non-surgical treatment options that can help alleviate pain and improve mobility. Healthcare providers are increasingly incorporating viscosupplementation into comprehensive osteoarthritis treatment plans, particularly for patients seeking alternatives to joint replacement surgery. In addition, favorable access to specialist care, advancements in diagnostic capabilities, and rising patient preference for minimally invasive procedures are contributing to market growth. Continued investments in musculoskeletal healthcare services and a focus on maintaining quality of life among older adults are expected to support the adoption of viscosupplementation therapies across Australia.

xAsia Pacific Single Injection Viscosupplementation Market

The Asia Pacific single injection viscosupplementation market represents an important segment within the broader viscosupplementation industry, driven by increasing demand for convenient and efficient osteoarthritis treatment options. Single injection formulations offer several advantages over multi-injection regimens, including improved patient compliance, fewer hospital visits, reduced procedural burden, and enhanced convenience for both patients and healthcare providers. These products are particularly attractive in countries with large aging populations and growing osteoarthritis prevalence, such as China, Japan, South Korea, and Australia. Advancements in cross-linked hyaluronic acid technologies have further improved the durability and effectiveness of single injection therapies. As healthcare systems increasingly emphasize outpatient care and patient-centric treatment approaches, adoption of single injection viscosupplementation products is expected to continue expanding across Asia Pacific.

Asia Pacific Hip Osteoarthritis Market

The Asia Pacific hip osteoarthritis market plays a significant role in supporting demand for viscosupplementation therapies, particularly as the prevalence of degenerative joint diseases continues to rise throughout the region. Aging populations, increasing obesity rates, sedentary lifestyles, and longer life expectancy are contributing to a growing burden of hip osteoarthritis in countries such as China, Japan, India, and Australia. Patients experiencing hip osteoarthritis increasingly seek non-surgical treatment options to manage pain, improve mobility, and delay joint replacement procedures. While viscosupplementation is more commonly used in knee osteoarthritis, ongoing clinical research and growing physician interest in hip joint applications are creating new opportunities within the market. Expanding orthopedic care infrastructure and rising awareness of early osteoarthritis management are expected to support future growth.

Asia Pacific Hospitals Market

The Asia Pacific hospitals market serves as a critical end-user segment for viscosupplementation therapies, accounting for a substantial share of treatment administration across the region. Hospitals are often the primary centers for osteoarthritis diagnosis, orthopedic consultations, imaging services, and injectable joint therapies. Growing investments in healthcare infrastructure, increasing hospital admissions related to musculoskeletal disorders, and rising demand for specialized orthopedic services are strengthening the role of hospitals in viscosupplementation adoption. Major healthcare facilities across China, Japan, India, Australia, and Southeast Asia are expanding orthopedic departments and outpatient treatment capabilities to address increasing osteoarthritis cases. Furthermore, hospitals provide access to skilled orthopedic specialists and advanced diagnostic technologies, making them key channels for viscosupplementation procedures. Continued healthcare modernization is expected to reinforce their market importance.

Asia-Pacific Viscosupplementation Market Segments

Product

• Single Injection
• Three Injection
• Five Injection

Application

• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand/Wrist Osteoarthritis
• Ankle/Foot Osteoarthritis
• Others

End User

• Hospitals
• Orthopedic clinics/Ambulatory Surgical Centers

Countries

• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand
• Rest of Asia Pacific

Companies have been covered from 5 viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Anika Therapeutics, Inc.
• Zimmer Biomet
• Smith & Nephew PLC
• F.Hoffmann-La Roche Ltd.
• Sanofi
• Chugai Pharmaceutical Co.
• Lifecore Biomedical
• LG Life Sciences Ltd.